Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Lacosamide: A Review in Focal-Onset Seizures in Patients with Epilepsy

Lacosamide: A Review in Focal-Onset Seizures in Patients with Epilepsy Lacosamide (Vimpat®) is a functionalized amino acid (available orally and intravenously) approved in the EU and the USA for use as monotherapy and adjunctive therapy for the treatment of focal-onset seizures in adults, adolescents and children aged ≥ 4 years with epilepsy. In adults and adolescents (aged ≥ 16 years), oral lacosamide as adjunctive therapy to other antiepileptic drugs was generally effective in reducing seizure frequency during short-term (up to 18 weeks) treatment, with efficacy sustained over the longer-term (up to 8 years). Moreover, patients were effectively switched from adjunctive oral lacosamide to the same dosage of intravenous lacosamide. Oral lacosamide was an effective conversion to monotherapy agent in this patient population and as monotherapy demonstrated noninferiority to carbamazepine controlled release in terms of seizure freedom. Antiepileptic benefits were maintained during longer-term (≤ 2 years) monotherapy. The antiepileptic efficacy of lacosamide in children aged ≥ 4 years has been extrapolated from data from adults and adolescents, with a similar response expected provided paediatric dosage adaptations are used and safety is demonstrated. Indeed, preliminary data demonstrated the efficacy of short-term (16 weeks) adjunctive lacosamide in patients aged ≥ 4 to < 17 years. Oral lacosamide was generally well tolerated over the short- and longer-term when administered as adjunctive therapy, a conversion to monotherapy agent and monotherapy in adults and adolescents and when administered as adjunctive therapy in children aged ≥ 4 years. Thus, lacosamide is a useful option for the management of focal-onset seizures across a broad age range, starting as early as 4 years of age. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png CNS Drugs Springer Journals

Lacosamide: A Review in Focal-Onset Seizures in Patients with Epilepsy

Hoy, Sheridan
CNS Drugs , Volume 32 (5) – May 21, 2018
Download PDF
12 pages

Loading next page...
 
/lp/springer-journals/lacosamide-a-review-in-focal-onset-seizures-in-patients-with-epilepsy-DVwZt4KRvY
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Neurology; Psychopharmacology; Pharmacotherapy; Neurosciences; Psychiatry
ISSN
1172-7047
eISSN
1179-1934
DOI
10.1007/s40263-018-0523-7
Publisher site
See Article on Publisher Site

Abstract

Lacosamide (Vimpat®) is a functionalized amino acid (available orally and intravenously) approved in the EU and the USA for use as monotherapy and adjunctive therapy for the treatment of focal-onset seizures in adults, adolescents and children aged ≥ 4 years with epilepsy. In adults and adolescents (aged ≥ 16 years), oral lacosamide as adjunctive therapy to other antiepileptic drugs was generally effective in reducing seizure frequency during short-term (up to 18 weeks) treatment, with efficacy sustained over the longer-term (up to 8 years). Moreover, patients were effectively switched from adjunctive oral lacosamide to the same dosage of intravenous lacosamide. Oral lacosamide was an effective conversion to monotherapy agent in this patient population and as monotherapy demonstrated noninferiority to carbamazepine controlled release in terms of seizure freedom. Antiepileptic benefits were maintained during longer-term (≤ 2 years) monotherapy. The antiepileptic efficacy of lacosamide in children aged ≥ 4 years has been extrapolated from data from adults and adolescents, with a similar response expected provided paediatric dosage adaptations are used and safety is demonstrated. Indeed, preliminary data demonstrated the efficacy of short-term (16 weeks) adjunctive lacosamide in patients aged ≥ 4 to < 17 years. Oral lacosamide was generally well tolerated over the short- and longer-term when administered as adjunctive therapy, a conversion to monotherapy agent and monotherapy in adults and adolescents and when administered as adjunctive therapy in children aged ≥ 4 years. Thus, lacosamide is a useful option for the management of focal-onset seizures across a broad age range, starting as early as 4 years of age.

Journal

CNS Drugs – Springer Journals

Published: May 21, 2018

References

  • The long-term safety of antiepileptic drugs
    Gaitatzis, A; Sander, J
  • Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology
    Fisher, RS; Cross, JH; French, JA
  • Epilepsy: new advances
    Moshé, SL; Perucca, E; Ryvlin, P
  • New developments in the treatment of partial-onset epilepsy
    Besag, FMC; Patsalos, PN
  • Lacosamide: a review of its use as adjunctive therapy in the management of partial-onset seizures
    Hoy, SM
  • Lacosamide: a review in focal seizures in patients with epilepsy
    Scott, LJ
  • Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures
    Ben-Menachem, E; Biton, V; Jatuzis, D
  • Development of lacosamide for the treatment of partial-onset seizures
    Doty, P; Hebert, D; Mathy, FX
  • Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial
    Chung, S; Sperling, MR; Biton, V
  • Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial
    Halász, P; Kälviäinen, R; Mazurkiewicz-Beldzińska, M
  • Examining the clinical utility of lacosamide
    Chung, S; Ben-Menachem, E; Sperling, M
  • A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs
    Sake, J-K; Hebert, D; Isojärvi, J
  • Efficacy of lacosamide by focal seizure subtype
    Sperling, MR; Rosenow, F; Faught, E
  • Efficacy and tolerability of brivaracetam compared to lacosamide, eslicarbazepine acetate, and perampanel as adjunctive treatments in uncontrolled focal epilepsy: results of an indirect comparison meta-analysis of RCTs
    Brigo, F; Bragazzi, NL; Nardone, R
  • Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical article
    Saria, MG; Corle, C; Hu, J
  • Outcome of cancer-related seizures in patients treated with lacosamide
    Toledo, M; Molins, A; Quintana, M
  • Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: a multicentre open-label trial
    Zadeh, WW; Escartin, A; Byrnes, W
  • Efficacy and safety of adjunctive lacosamide for the treatment of partial-onset seizures in Chinese and Japanese adults: a randomized, double-blind, placebo-controlled study
    Hong, Z; Inoue, Y; Liao, W
  • Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures
    Biton, V; Rosenfeld, WE; Whitesides, J
  • Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a phase III open-label extension trial
    Husain, A; Chung, S; Faught, E
  • Safety and efficacy of adjunctive lacosamide among patients with partial-onset seizures in a long-term open-label extension trial of up to 8 years
    Rosenfeld, W; Fountain, NB; Kaubrys, G
  • Long-term adjunctive lacosamide treatment in patients with partial-onset seizures
    Rosenow, F; Kelemen, A; Ben-Menachem, E
  • A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: the VITOBA study
    Runge, U; Arnold, S; Brandt, C
  • Adjunctive lacosamide: 5 years’ clinical experience
    Stephen, LJ; Kelly, K; Parker, P
  • Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA
    Villanueva, V; López-Gomáriz, E; López-Trigo, J
  • Control of seizures in different stages of partial epilepsy: LACO-EXP, a Spanish retrospective study of lacosamide
    Villanueva, V; López, FJ; Serratosa, JM
  • Clinical experience with oral lacosamide as adjunctive therapy in adult patients with uncontrolled epilepsy: a multicentre study in epilepsy clinics in the United Kingdom (UK)
    Flores, L; Kemp, S; Colbeck, K
  • Early add-on lacosamide in a real-life setting: results of the REALLY study
    Villanueva, V; Garcés, M; López-Gomáriz, E
  • Conversion to lacosamide monotherapy in the treatment of focal epilepsy: results from a historical-controlled, multicenter, double-blind study
    Wechsler, RT; Li, G; French, J
  • Long-term exposure and safety of lacosamide monotherapy for the treatment of partial-onset (focal) seizures: results from a multicenter, open-label trial
    Vossler, DG; Wechsler, RT; Williams, P
  • Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial
    Baulac, M; Rosenow, F; Toledo, M
  • Lacosamide monotherapy in clinical practice: a retrospective chart review
    Villanueva, V; Giraldez, BG; Toledo, M
  • A review of the new antiepileptic drugs for focal-onset seizures in pediatrics: role of extrapolation
    Arzimanoglou, A; D’Cruz, O; Nordli, D
  • Efficacy and tolerability of lacosamide in the concomitant treatment of 130 patients under 16 years of age with refractory epilepsy: a prospective, open-label, observational, multicenter study in Spain
    Casas-Fernández, C; Martínez-Bermejo, A; Rufo-Campos, M
  • Efficacy and safety of lacosamide as an adjunctive therapy for refractory focal epilepsy in paediatric patients: a retrospective single-centre study
    Toupin, J-F; Lortie, A; Major, P
  • Lacosamide as an adjunctive therapy in pediatric patients with refractory focal epilepsy
    Kim, JS; Kim, H; Lim, BC
  • Efficacy and tolerability of oral lacosamide as adjunctive therapy in pediatric patients with pharmacoresistant focal epilepsy
    Gavatha, M; Ioannou, I; Papavasiliou, AS
  • Experience with lacosamide in a series of children with drug-resistant focal epilepsy
    Guilhoto, LMFF; Loddenkemper, T; Gooty, VD
  • Intravenous lacosamide as short-term replacement for oral lacosamide in partial-onset seizures
    Krauss, G; Ben-Menachem, E; Mameniskiene, R
  • Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamide-naive patients with partial-onset seizures
    Fountain, NB; Krauss, G; Isojarvi, J
  • Safety and tolerability of lacosamide as adjunctive therapy in adults with partial-onset seizures: analysis of data pooled from three randomized, double-blind, placebo-controlled trials
    Biton, V; Gil-Nagel, A; Isojarvi, J
  • Epilepsy management: newer agents, unmet needs, and future treatment strategies
    Ventola, CL
  • Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes
    Glauser, T; Ben-Menachem, E; Bourgeois, B
  • Review of therapeutic options for adjuvant treatment of focal seizures in epilepsy: focus on lacosamide
    Becerra, JL; Ojeda, J; Corredera, E
  • Sodium channel blockers in the treatment of epilepsy
    Brodie, MJ
  • Lacosamide cardiac safety: a thorough QT/QTc trial in healthy volunteers
    Kropeit, D; Johnson, M; Cawello, W
  • Advances in epilepsy treatment: lacosamide pharmacokinetic profile
    Cawello, W; Stockis, A; Andreas, JO